Olanzapine in Patients With Advanced Cancer and Weight Loss

PHASE1CompletedINTERVENTIONAL
Enrollment

57

Participants

Timeline

Start Date

October 31, 2006

Primary Completion Date

December 31, 2013

Study Completion Date

December 31, 2013

Conditions
Advanced CancerWeight Loss
Interventions
DRUG

Olanzapine

2.5 mg by mouth (PO) Daily x 28 days, increasing about every 3-14 days in increments of 2.5-5 mg until the designated dose for that cohort is reached.

Trial Locations (1)

77030

UT MD Anderson Cancer Center, Houston

All Listed Sponsors
lead

M.D. Anderson Cancer Center

OTHER

NCT00489593 - Olanzapine in Patients With Advanced Cancer and Weight Loss | Biotech Hunter | Biotech Hunter